Nrx Pharmaceuticals Inc Quick Ratio (NRXP) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nrx Pharmaceuticals Inc   (NASDAQ: NRXP)

Nrx Pharmaceuticals Inc 's Quick Ratio

NRXP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nrx Pharmaceuticals Inc 's Cash & cash equivalent grew by 297.53 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Nrx Pharmaceuticals Inc 's Quick Ratio to 0.79, Quick Ratio remained below Nrx Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Nrx Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2182, from total ranking in the first quarter 2026 at 2629.

Explain Quick Ratio?
How much Cash & cash equivalents NRXP´s has?
What are NRXP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NRXP Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -16.26 % -23.13 % 30.71 % 99.98 % 578.06 %
Y / Y Cash & cash equivalent Change 817.04 % 21 % 440.33 % 336.45 % 53.32 %
Quick Ratio MRQ 0.79 0.27 0.27 0.18 0.07
NRXP's Total Ranking # 2182 # 2629 # 2878 # 2953 # 3098
Seq. Current Liabilities Change 34.55 % -11.9 % -29.6 % 0.35 % 23.52 %
Seq. Cash & cash equivalent Change 297.53 % -13.9 % 8.53 % 146.87 % -47.55 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 371
Healthcare Sector # 672
Overall Market # 2182


Quick Ratio Statistics
High Average Low
4.82 1.08 0
(Dec 31 2017)   (Mar 31 2021)




Financial Statements
Nrx Pharmaceuticals Inc 's Current Liabilities $ 34 Millions Visit NRXP's Balance sheet
Nrx Pharmaceuticals Inc 's Cash & cash equivalent $ 27 Millions Visit NRXP's Balance sheet
Source of NRXP's Sales Visit NRXP's Sales by Geography


Cumulative Nrx Pharmaceuticals Inc 's Quick Ratio

NRXP's Quick Ratio for the trailling 12 Months

NRXP Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 11.14 % 66.67 % 138.42 % 155.86 % 121.65 %
Y / Y Cash & cash equivalent TTM Growth 318.98 % 133.55 % 271.69 % 80.64 % -30.91 %
Quick Ratio TTM 0.38 0.18 0.16 0.13 0.1
Total Ranking TTM # 4062 # 3008 # 3007 # 3307 # 2966
Seq. Current Liabilities TTM Growth -4.88 % -5.32 % 4.95 % 17.59 % 42.64 %
Seq. Cash & cash equivalent TTM Growth 96.63 % 4.97 % 37.19 % 47.96 % 9.61 %

Quick ratio ranking by company, industry and sector >> Back to NRXP Financial Strength Comparisons >> Go to Compare NRXP Quick Ratio to its Competitors

On the trailing twelve months basis NRXP Cash & cash equivalent more than doubled by 817.04 % in Q2 2026 year on year, while Current Liabilities grew to $34 millions, this led to increase in in Nrx Pharmaceuticals Inc 's Quick Ratio to 0.38, Quick Ratio remained below NRXP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Nrx Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3008 to 4062.

Explain Quick Ratio?
How much Cash & cash equivalents NRXP´s has?
What are NRXP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 441
Healthcare Sector # 905
Within the Market # 4062


trailing twelve months Quick Ratio Statistics
High Average Low
2.01 0.58 0.08
(Sep 30 2020)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Xeris Biopharma Holdings Inc   2.16 $ 243.494  Millions$ 112.826  Millions
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions

Date modified: 2026-09-26T07:39:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.